9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current
- 1 September 1987
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 141 (1) , 153-157
- https://doi.org/10.1016/0014-2999(87)90424-9
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986
- CHOLINERGIC APPROACHES TO THE TREATMENT OF ALZHEIMER'S DISEASEBritish Medical Bulletin, 1986
- HETEROGENEITY OF PRESYNAPTIC MUSCARINIC RECEPTORS REGULATING NEUROTRANSMITTER RELEASE IN THE RAT-BRAIN1984
- The effects of 4-aminopyridine and tetrodotoxin on the release of acetylcholine from rat striatal slicesNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1983
- Independent in vitro regulation by the D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+-stimulated release of acetylcholine from rat neostriatumBrain Research, 1982
- THA—A Review of the Literature and Its Use in Treatment of Five Overdose PatientsClinical Toxicology, 1980
- THE OUTPUT PER STIMULUS OF ACETYLCHOLINE FROM CEREBRAL CORTICAL SLICES IN THE PRESENCE OR ABSENCE OF CHOLINESTERASE INHIBITIONBritish Journal of Pharmacology, 1974
- Enzyme Inhibiting Action of Tetrahydroaminoacridine and its Structural FragmentsJournal of Pharmacy and Pharmacology, 1962